Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sandoz Expects Imminent US Pegfilgrastim Action

Seven Months Have Passed Since Refiling With FDA

Executive Summary

Sandoz chief Richard Saynor remains confident in the firm’s US pegfilgrastim filing, even though it has been with the FDA for more than six months.

You may also be interested in...

Sandoz Gets Approval For US Pegfilgrastim

Sandoz has finally received a much-awaited FDA approval for its pegfilgrastim biosimilar, Ziextenzo, which will be launched in the US “as soon as possible this year.”

Kanjinti and Mvasi Make ‘Solid Start’ In US

Launching its Kanjinti and Mvasi trastuzumab and bevacizumab biosimilars ‘at risk’ in July generated third-quarter sales of $81m for Amgen, contributing nearly half of global biosimilar turnover of $173m.

Sandoz And Polpharma Strike Global Deal For Natalizumab

Polpharma and Sandoz have stuck a global licensing deal that gives the Novartis subsidiary rights to market the Polish firm’s biosimilar natalizumab rival to Biogen’s Tysabri.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts